Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-04-29 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-04-29 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an upcoming Board Meeting scheduled for May 14, 2025, where the Board will consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025, and recommend dividends if any. It also mentions the closure of the trading window for insiders. The document is an intimation of a Board Meeting and does not contain the financial results themselves or detailed financial data. It is a regulatory announcement pursuant to SEBI Listing Regulations. The document length is short (2329 characters), and it serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document, not as the actual financial report or Board/Management Information about changes in directors or management.
2025-04-29 English
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for May 14, 2025. The purpose of the meeting includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, and recommending dividends. It also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document does not contain the financial results themselves but is an announcement of the meeting where these results will be approved and possibly announced. The document length is short (2329 characters), and it serves as an intimation rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification to the stock exchange about the board meeting and upcoming results, rather than the results or report itself.
2025-04-29 English
Intimation regarding allotment of 51495 shares under ESOP.
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It specifies the number of shares allotted, the exercise of vested options by employees, and the resulting increase in the company's paid-up share capital. The document references compliance with SEBI Listing Regulations and is signed by the company secretary. The content is an announcement of a capital change (share allotment) rather than a full financial report or other types of filings. The document length is short (2014 characters), and it is clearly an announcement of a share capital change due to ESOP exercise. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-04-28 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It specifies the number of shares allotted, the increase in issued and paid-up share capital, and references compliance with SEBI Listing Regulations. The content is an announcement of a capital change due to share allotment, not a full financial report or detailed analysis. The document length is short (2014 characters), and it is clearly an announcement of a share capital change rather than a report or presentation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2025-04-28 English
Lupin Receives Approval from U. S. FDA for Tolvaptan Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of U.S. FDA approval for its Abbreviated New Drug Application for Tolvaptan Tablets. It includes details about the product, exclusivity, manufacturing, and company background. There are no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (4471 characters) and serves as an announcement of a regulatory approval event rather than a financial or management report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement related to a product approval, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-04-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.